PULMONARY HYPERTENSION IN β-THALASSEMIA MAJOR AND THE ROLE OF L-CARNITINE THERAPY

REFERENCES

• Aessopos A, Farmakis D, Hatziliami A, et al. Cardiac status in well-treated patients with thalassemia major. Eur J Haematol 2004; 73: 359–366
   PubMed Web of Science ®Google Scholar
• Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC. Heart failure in beta-thalassemia syndromes: A decade of progress. Am J Med 2005; 118: 957–967
   PubMed Web of Science ®Google Scholar
• Du ZD, Roguin N, Milgram E, Saab K, Koren A. Pulmonary hypertension in patients with thalassemia major. Am Heart J 1997; 134: 532–537
   PubMed Web of Science ®Google Scholar
• Walter H. L–Carnitine. Arch Dis Child 1996; 74: 475–458
   PubMed Web of Science ®Google Scholar
• Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther 1991; 13: 2–21
   PubMed Web of Science ®Google Scholar
• Colonna P, Iliceto S. Myocardial infarction and left ventricular remodling: Results of the CEDIM trial. Carnitine Echocardiografia Digitalizzata infarto Miocardico. Am Heart J 2000; 139: S124–S130
   Web of Science ®Google Scholar
• El-Beshlawy A, Abd El Raouf E, Mostafa F, et al. Diastolic dysfunction and pulmonary hypertension in sickle cell anemia: Is there a role for L-carnitine treatment?. Acta Haematol 2006; 115: 91–96
   PubMed Web of Science ®Google Scholar
• Sahn DJ, De Maria A, Kissio J, Weyman A. The Committee on M-mode Standardization of the American Society of Echocardiography: Results of a survey of echocardiography measurements. Circulation 1978; 58: 1072–1083
   PubMed Web of Science ®Google Scholar
• Schiller NB, Shah PM, Crawford M. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards Subcommittee. J Am Soc Echocardiogr 1989; 2: 358–367
   PubMed Web of Science ®Google Scholar
• Cohen Gl, Pietrolungo JF, Thomas JD, Klein AL. A practical guide to assessment of ventricular diastolic function using Doppler echocardiography. J Am Coll Cardiol 1996; 27: 1753–1760
   PubMed Web of Science ®Google Scholar
• Andren B, Lind L, Hedenstierna G, Lithell H. Left ventricular hypertrophy and geometry in a population sample of elderly males. Eur Heart J 1996; 17: 1800–1807
   PubMed Web of Science ®Google Scholar
• Dabestani A, Mahan G, Gardin J. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. Am J Cardiol 1987; 59: 662–668
   PubMed Web of Science ®Google Scholar
• Chan KL, Currie PJ, Seward JB, Hagler DJ, Mair DD, Tajik AJ. Comparison of three Doppler ultra-sound methods in the prediction of pulmonary artery diseases. J Am Coll Cardiol 1987; 9: 549–954
   PubMed Web of Science ®Google Scholar
• Kato GJ, Onyekwere OC, Galdwin MT. Pulmonary hypertension in sickle cell disease: Relevance to children. Pediatr Hematol Oncol 2007; 24: 159–170
   PubMed Web of Science ®Google Scholar
• Ambrusko SJ, Gunawarena S, Sakara A, et al. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatr Blood Cancer 2006; 47: 907–913
   PubMed Web of Science ®Google Scholar
• Saunders DB, Trapp GR. Basic and Clinical Biostatistics, 3, , et al. Appleton & Lang, Norwalk, CT 2001
   Google Scholar
• Kremastinos DT, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP, Toutouzas PK. Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation 1993; 88: 1127–1135
   PubMed Web of Science ®Google Scholar
• Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001; 97: 3411–3416
   PubMed Web of Science ®Google Scholar
• Spirito P, Lupi G, Melevendi C, Vecchio C. Restrictive diastolic abnormalities identified by Doppler echocardiography in patients with thalassemia major. Circulation 1990; 82: 188–194
   PubMed Web of Science ®Google Scholar
• Okpala IE. New therapies for sickle cell disease. Hematol Oncol Clin North Am 2005; 19: 975–987
   PubMed Web of Science ®Google Scholar
• Rizos I, Primokiropoulos A, Hadjinikolau L. Hemodynamical effects of L-carnitine on patients with congestive heart failure due to dilated cardiomyopathy. Eur Heart J 1995; 16: 181–185
   Google Scholar
• El-Beshlawy A, Ragab L, Fattah AA, et al. Improvement of cardiac function in thalassemia major treated with L-carnitine. Acta Haematol 2004; 111: 143–148
   PubMed Web of Science ®Google Scholar
• Kothari SS, Sharma M. L-Carnitine in children with idiopathic dilated cardiomyopathy. Indian Heart J 1998; 50: 59–61
   PubMedGoogle Scholar
• Anand I, Chandrashekhan Y, De-Giuli F, Pasini E, Mazzoletti A. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity and hormones in patients with congestive heart failure. Cardiovasc. Drugs Ther 1998; 12: 291–299
   PubMed Web of Science ®Google Scholar
• Corr PB, Creer MM, Yamada KA, Saffitz JE. Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest 1989; 83: 927–936
   PubMed Web of Science ®Google Scholar
• Yesilipek MA, Hazar V, Yegin O. l-Carnitine treatment in β-thalassemia major. Acta Hematol 1998; 100: 162–163
   PubMed Web of Science ®Google Scholar